---
title: "Designing Microbiome Trials: Gut Microbiota for Health World Summit 2022"
subtitle: ""
author: "Brendan J. Kelly, MD, MS"
institute: "Infectious Diseases & Epidemiology<br><br>![](penn_logos/Penn-Shield-Logotype-White-over-Blue-RGB-Expanded.svg){width=160px}" 
date: "12 March 2022" #"`r format(Sys.Date(), '%d %B %Y')`"
output:
  xaringan::moon_reader:
    css: xaringan-themer-inferno-grids-fade.css
    lib_dir: libs
    chakra: libs/remark-latest.min.js
    seal: false
    nature:
      ratio: 16:9
      highlightStyle: github
      highlightLines: true
      countIncrementalSlides: false
      slideNumberFormat: "%current%"

---
exclude: true

```{r setup, include=FALSE, echo=FALSE, message=FALSE, error=FALSE, include=FALSE, comment=FALSE}
options(htmltools.dir.version = FALSE)
xaringan::summon_remark()
library(tidyverse)
library(gt)

```

```{r xaringan-tile-view, echo=FALSE, message=FALSE, error=FALSE, include=FALSE, comment=FALSE}
xaringanExtra::use_tile_view()
xaringanExtra::use_webcam()
xaringanExtra::use_tachyons()
xaringanExtra::use_animate_css()
xaringanExtra::use_share_again()
#xaringanExtra::use_scribble(pen_color = "#56106E")
```

---
class: top left hide-count
background-image: url(img/cdc-QEU-QgIOJKA-unsplash_darkest.jpg)
background-size: cover

.move-top20[
.title-text[<span style='font-size:0.75em'>Designing Microbiome Trials</span>]  
.title-subtext[<span style='font-size:1.2em'>Unique Challenges & Considerations</span>]  
]  
  
.callout-url-leftcorner[
.title-nametext[
Brendan J. Kelly, MD, MS  
Infectious Diseases, Microbiology & Epidemiology  
University of Pennsylvania  

GMFH World Summit  
12 March 2022
]
]

.footnote-right[<span style='color: white'>photo: CDC @unsplash</span>]  



---

## Disclosures  

.pad-left[  

- No conflicts of interest.  

- Research supported by:

    - NIAID K23 AI121485  
    
    - CDC BAA 200-2016-91964  
    
    - CDC BAA 200-2016-91937  
    
    - CDC BAA 200-2018-02919  
    
    - CDC BAA 200-2021-10986   

]


---
class: full-screen hide-count

<div class="grid-3-1">
<div class="extension-tile gridset-a animated flipInY"><div>How Randomized Trials Go Wrong</div></div>
</div>





---
layout: false
class: full-screen hide-count

<div class="grid-3-1">
<div class="extension-tile gridset-a"><div>How Randomized Trials Go Wrong</div></div>
<div class="extension-tile gridset-b animated flipInX"><div>RCTs of FMT</div></div>
</div>





---
layout: false
class: full-screen hide-count

<div class="grid-3-1">
<div class="extension-tile gridset-a"><div>How Randomized Trials Go Wrong</div></div>
<div class="extension-tile gridset-b"><div>RCTs of FMT</div></div>
<div class="extension-tile gridset-c animated bounceInDown"><div>Strategies for<br>the LBP Era</div></div>
</div>





---
layout: false
class: full-screen hide-count

<div class="grid-3-1">
<div class="extension-tile gridset-a"><div>How Randomized Trials Go Wrong</div></div>
<div class="extension-tile gridset-grey"><div>RCTs of FMT</div></div>
<div class="extension-tile gridset-grey"><div>Strategies for<br>the LBP Era</div></div>
</div>



---

## "Understanding and Misunderstanding RCTs"  

.pad-left[  
  
- Randomized clinical trials = gold standard for clinical research:    
  
    - balance known & unknown confounders       
    
    - powerful tool to measure causal effects    
        
- RCTs can still mislead:  

    - selection bias (subjects ≠ population)

    - "trial interventions are interactions" resulting in heterogenous effects    
    (subject features modify effect of trial intervention)  

    - "subjects aren't even fully representative of themselves"  
    (<u>time-varying features</u> also interact with trial intervention)
   
]

.footnote-left[Deaton & Cartwright _Social Science & Medicine_ 2018; Andrew Gelman] 


---

## Time-Varying Gut Microbiota  

```{r omega_squared, echo=FALSE, message=FALSE, warning=FALSE, fig.align='center', out.width='110%'}

knitr::include_graphics(path = "./img/kelly_bioinf_2016.png")


```


.footnote-left[Kelly et al _Bioinformatics_ 2015] 


---

## Time-Varying Gut Microbiota  

.pad-left[  
  
- Dietary changes and antibiotics exert large effects...  

 ... larger effects when followed by colonization from healthcare environment   

- Gut microbiota at time of intervention ≠ microbiota at time of enrollment:  

    - misclassification of inclusion criteria kills randomized trials  
    
    - "the medicine doesn't work if the patient isn't sick"  
    
    - microbiome trials run a **high risk of eligibility misclassification**   

]  


.footnote-left[Kelly et al _ICHE_ 2021] 


---

## How Microbiota Trials Go <u>Right</u>  

.pad-left[

- RCTs can overcome effect modification by changing gut microbiota if:  

    - very precise disease phenotype (less likely time-varying gut microbiota)  
    
    - precision medicine: tailor treatment to near-real-time measures of gut microbiota  
    
    - interventions with huge effects (antibiotic conditioning prior to FMT)  
  
]



---
layout: false
class: full-screen hide-count

<div class="grid-3-1">
<div class="extension-tile gridset-grey"><div>How Randomized Trials Go Wrong</div></div>
<div class="extension-tile gridset-b"><div>RCTs of FMT</div></div>
<div class="extension-tile gridset-grey"><div>Strategies for<br>the LBP Era</div></div>
</div>



---

## Fecal Microbiota Transplant (FMT) Trials      
  
.pad-left[  
  
- FMT in Infectious Diseases @ the University of Pennsylvania:  
  
    - FMT dose finding for recurrent _C. difficile_ infection (NCT03973697) 
    
    - serial FMT for severe _C. difficile_ infection (NCT03970200)         
    
    - FMT for MDRO colonization (CDC sponsored)    
    
- Successful applications of FMT:     
  
    - recurrent & severe _C. difficile_, inflammatory bowel diseases, potentiation of anti-PD1 immunotherapy, MDRO colonization, food allergy mitigation  
    
    - heterogeneity of gut microbiota community composition?  
    
]  



---

### Microbial Heterogeneity in _C. difficile_  

.pad-left[  
  
- **Aim**: microbiome features that discriminate _C. difficile_ colonization / infection    

- **Population**: 384 consecutive positive _C. difficile_ tests (in- & outpatient)   
    
```{r, warning=FALSE, error=FALSE, echo=FALSE, message=FALSE}
read_rds("./tabs/cd_specimen_count.rds") %>%
    tab_options(column_labels.font.size = 16,
                column_labels.font.weight = "bold",
                table.font.size = 16) %>%
  identity() -> cd_tab
cd_tab
```
    
- **Sampling**: stool 16S rRNA gene sequencing & 16S rRNA gene qPCR  
    
- **Comparison**: toxin EIA+ (infection) versus NAAT+ only (colonization)     
    
- **Outcome**: EIA+, with fecal lactoferrin as sensitivity analysis    
  
]  

.footnote-left[Tkatch et al _ASM World Microbiome Forum_ 2021]  



---
background-image: url(figs/p_toxineia_clostridioides_boxplot_tp.png)
background-size: 65%


.footnote-left[Tkatch et al _ASM World Microbiome Forum_ 2021]  


---
background-image: url(figs/p_cdi_cat_fecal_lacto_boxplot_tp.png)
background-size: 65%


.footnote-left[Tkatch et al _ASM World Microbiome Forum_ 2021]  



---

## Phenotype Definitions & FMT Outcomes  

.pad-left[  

- The success of FMT depends on homogeneity of gut microbiota phenotype:  

    - moderate heterogeneity of _C. difficile_ infection  
    
    - large heterogeneity across IBD  

- Pre-FMT antibiotic conditioning as a method to enforce homogeneity:  

    - which antibiotics are used?
    
    - effects of other medications active on gut microbiota (e.g., PPIs)?

    - FMT as part of a bundled intervention?

]


---
layout: false
class: full-screen hide-count

<div class="grid-3-1">
<div class="extension-tile gridset-grey"><div>How Randomized Trials Go Wrong</div></div>
<div class="extension-tile gridset-grey"><div>RCTs of FMT</div></div>
<div class="extension-tile gridset-c"><div>Strategies for<br>the LBP Era</div></div>
</div>



---

## Into the LBP Era  

.pad-left[

- Live biotherapeutic products (LBPs) replacing FMT:  

    - Seres, Rebiotix, Vedanta, Finch...  
    
    - ensure greater homogeneity of intervention
    
    - larger effects?  

- Are bundled interventions still necessary?  

    - role for pre-LBP antibiotic conditioning?  
    
    - restrictions on medications that reshape gut microbial communities?
    
    - role for precision medicine & pre-treatment microbiota profiles?  

]


---
layout: false
class: full-screen hide-count

<div class="grid-3-1">
<div class="extension-tile gridset-a animated flipInY"><div>How Randomized Trials Go Wrong</div></div>
<div class="extension-tile gridset-b animated flipInX"><div>RCTs of FMT</div></div>
<div class="extension-tile gridset-c animated flipInY"><div>Strategies for<br>the LBP Era</div></div>
</div>


---

## Topics for Discussion    

.pad-left[

- Every RCT intervention is an interaction:

    - gut microbiota community composition varies over time  
    
    - account for changes in diet & medications, environment  

- RCTs can overcome effect modification if:  

    - very precise disease phenotype (less likely time-varying gut microbiota)  
    
    - precision medicine: tailor treatment to near-real-time measures of gut microbiota  
    
    - interventions with huge effects (antibiotic conditioning prior to FMT)  

- How to translate lessons from FMT trials to the LBP era?   

]



---
exclude: true

## Acknowledgements    

.pull-left[
- __ARES Group @ Penn__
Sean Loughrey, Laura Cowden, Laurel Glaser, Kyle Rodino,   
Magda Wernovsky, Emily Reesey, Erik Clarke, Michael David,
Matt Ziegler, Lauren Dutcher, Ebbing Lautenbach, Jim Harrigan, Hatem Abdallah

- __Bushman Laboratory @ Penn__
Arwa Abbas, Aoife Roche, Andrew Marques,
Aubrey Bailey, Jacob Leiby,
Rick Bushman

- __PennCHOP Microbiome Program__
Lisa Mattei, Casey Hofstaedter, Huanjia Zhang, Kyle Bittinger

]


.pull-right[
- __Collman Laboratory @ Penn__
Ize Imai, Aurea Simon Soro, John McGinniss, Ron Collman

- __Division of ID @ Penn__
Ian Frank, Pablo Tebas, Robert Gross, Emily Blumberg

- __Rutgers University & Penn DBEI__
Jason Roy, Arman Oganisian
  
- __CDC Prevention Epicenters__
Clifford McDonald, Alison Laufer Halpin
  
- __Funding__
<u>CDC</u>: BAAs 200-2016-91964, 200-2018-02919, 200-2021-10986,
200-2021-10986 & <u>NIAID</u>: K23 AI121485

]

.center[
### brendank@pennmedicine.upenn.edu
]



---
class: middle center hide-count
background-image: url(img/cdc-QEU-QgIOJKA-unsplash_darkest.jpg)
background-size: cover

.title-subtext[brendank@pennmedicine.upenn.edu]

.callout-url-bottom[  
.fade-in[<span style="font-size:0.5em; color:white">slides ↓ </span>]  
<span style="link-color:white">[bjklab.org](http://www.bjklab.org)</span>  
]  


